Alligator Bioscience AB (FRA:7AL0) 5-Year EBITDA Growth Rate: 61.70% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Alligator Bioscience AB 5-Year EBITDA Growth Rate?

Alligator Bioscience AB FRA:7AL0 5-Year EBITDA Growth Rate is 61.70% as of Jun. 2026. The stock has 6 warning signs investors should review.

Alligator Bioscience AB's EBITDA per Share for the three months ended in Jun. 2026 was €-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 82.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 61.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Alligator Bioscience AB was 82.30% per year. The lowest was -91.70% per year. And the median was 12.35% per year.

Alligator Bioscience AB  (FRA:7AL0) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Alligator Bioscience AB 5-Year EBITDA Growth Rate Related Terms

FRA:7AL0 vs VRTX, REGN, MRNA: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's 5-Year EBITDA Growth Rate falls into.


Alligator Bioscience AB 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 61.70% mean?
Alligator Bioscience AB (FRA:7AL0) has a 5-Year EBITDA Growth Rate of 61.70% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's 5-Year EBITDA Growth Rate too high?
Alligator Bioscience AB's current 5-Year EBITDA Growth Rate is 61.70%.
How does Alligator Bioscience AB's 5-Year EBITDA Growth Rate compare to VRTX and REGN?
Alligator Bioscience AB's 5-Year EBITDA Growth Rate of 61.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current 5-Year EBITDA Growth Rate is 61.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current 5-Year EBITDA Growth Rate of 61.70%. The current 5-Year EBITDA Growth Rate is 61.70%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current 5-Year EBITDA Growth Rate is 61.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.